Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.38 |
| ▸ | TSHR | P16473 | 3/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.38 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28712321 | 0.83 | LMNA (0.35) | LMNATSHRCHRM2CHRM4CHRM5 | |
| SCHEMBL5100758 | 0.83 | GABRR1 (0.35) | LMNATSHRCHRM2CHRM4CHRM5 | |
| SCHEMBL28418994 | 0.82 | LMNA (0.38) | LMNATSHRCHRM2CHRM4CHRM5 | |
| SCHEMBL1829129 | 0.82 | LMNA (0.38) | LMNATSHRCHRM2CHRM4CHRM5 | |
| SCHEMBL20416250 | 0.82 | LMNA (0.41) | LMNATSHRCHRM2CHRM4CHRM5 | |
| SCHEMBL28415266 | 0.82 | LMNA (0.38) | LMNATSHRCHRM2CHRM4CHRM5 | |
| SCHEMBL24623 | 0.80 | LMNA (0.36) | LMNATSHRCHRM2CHRM4CHRM5 | |
| SCHEMBL4966129 | 0.80 | LMNA (0.36) | LMNATSHRCHRM2CHRM4CHRM5 | |
| SCHEMBL2474842 | 0.80 | LMNA (0.36) | LMNATSHRCHRM2CHRM4CHRM5 | |
| SCHEMBL16330481 | 0.80 | LMNA (0.36) | LMNATSHRCHRM2CHRM4CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137819-A1 | FOLLICLE-STIMULATING HORMONE RECEPTOR (FSHR) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY INC (US) | 2026-05-21 | — | — | US | disclosed |
| US-12595318-B2 | — | — | 2026-04-07 | — | — | US | disclosed |
| US-12558432-B2 | Biocompatible polymeric drug carriers for delivering active agents | CIS BIOPHARMA AG (CH) | 2026-02-24 | — | — | US | disclosed |
| US-12479933-B2 | Crosslinked alginic acid structure | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2025-11-25 | — | — | US | disclosed |
| US-20250223281-A1 | ANTIDIABETIC COMPOUNDS AND COMPOSITIONS | REZUBIO PHARMACEUTICALS CO., LTD (CN) | 2025-07-10 | — | — | US | disclosed |
| EP-3778653-B1 | NOVEL REACTIVE ALGINIC ACID DERIVATIVES | MOCHIDA PHARM CO LTD (JP) | 2025-07-09 | — | — | EP | disclosed |
| EP-4406606-A2 | ANTIBODY DRUG CONJUGATES (ADCS) AND ANTIBODY PRODRUG CONJUGATES (APDCS) WITH ENZYMATICALLY CLEAVABLE G | Bayer Pharma Aktiengesellschaft (DE) | 2024-07-31 | — | — | EP | disclosed |
| US-20240174772-A1 | NOVEL CROSSLINKED ALGINIC ACID | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2024-05-30 | — | — | US | disclosed |
| US-11932708-B2 | Crosslinked alginic acid | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2024-03-19 | — | — | US | disclosed |
| CN-111801322-B | Kinase inhibitors for the treatment of central and peripheral nervous system disorders | 迈阿密大学 | 2024-03-15 | — | — | CN | disclosed |
| US-20120277228-A1 | Novel Azaheterocyclic Compounds | MERCK PATENT GMBH (DE) | 2012-11-01 | — | — | US | disclosed |
| EP-2462141-A1 | NOVEL AZAHETEROCYCLIC COMPOUNDS | Merck Patent GmbH (DE) | 2012-06-13 | — | — | EP | disclosed |
| US-20120065202-A1 | PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | CELLZOME LIMITED (GB) | 2012-03-15 | — | — | US | disclosed |
| EP-2406258-A1 | PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | Cellzome Limited (GB) | 2012-01-18 | — | — | EP | disclosed |
| US-20110251547-A1 | TRANSFECTION WITH MAGNETIC NANOPARTICLES AND ULTRASOUND | INTELLIGENTNANO INC. (CA) | 2011-10-13 | — | — | US | disclosed |
| WO-2011017009-A1 | NOVEL AZAHETEROCYCLIC COMPOUNDS | MERCK PATENT GMBH (DE) | 2011-02-10 | — | — | WO | disclosed |
| WO-2010103094-A1 | PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | CELLZOME LIMITED (GB) | 2010-09-16 | — | — | WO | disclosed |
| EP-1856048-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | Theravance, Inc. (US) | 2007-11-21 | — | — | EP | disclosed |
| WO-2006098999-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2006-09-21 | — | — | WO | disclosed |
| WO-2006099091-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2006-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12558432-B2 | Biocompatible polymeric drug carriers for delivering active agents | MSR1, CD47, SLC43A1 | LMNA 696/4885TSHR 1079/4885CHRM2 893/4885 |
| US-20120277228-A1 | Novel Azaheterocyclic Compounds | PCNA, MCL1, MYC | LMNA 2699/4885TSHR 2685/4885CHRM2 4710/4885 |
| US-20120065202-A1 | PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | MTOR, RICTOR, RPTOR | LMNA 2684/4885TSHR 2833/4885CHRM2 4135/4885 |
| US-20250223281-A1 | ANTIDIABETIC COMPOUNDS AND COMPOSITIONS | GPR119, GLP1R, GPR65 | LMNA 3812/4885TSHR 1353/4885CHRM2 422/4885 |
| US-20260137819-A1 | FOLLICLE-STIMULATING HORMONE RECEPTOR (FSHR) TARGETED THERAPEUTICS AND USES THEREOF | FSHR, GNRHR, LHCGR | LMNA 3318/4885TSHR 5/4885CHRM2 3020/4885 |
| US-12595318-B2 | — | ALG1, ALG8, FUCA1 | LMNA 2167/4885TSHR 4227/4885CHRM2 2847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.